{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:27:18Z","timestamp":1789140438444,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd011044.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000}}],"reference-count":375,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011044.pub3","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T07:00:05Z","timestamp":1733382005000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chemotherapy and radiotherapy for advanced pancreatic cancer"],"prefix":"10.1002","volume":"2024","author":[{"given":"Lucy","family":"Haggstrom","sequence":"additional","affiliation":[{"name":"Medical Oncology; The Kinghorn Cancer Care Centre, St Vincent's Hospital; Sydney Australia"},{"name":"Medical Oncology; Illawarra Shoalhaven Local Health District; Wollongong Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine and Health; University of New South Wales; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Yen","family":"Chan","sequence":"additional","affiliation":[{"name":"Medical Oncology; The Kinghorn Cancer Care Centre, St Vincent's Hospital; Sydney Australia"},{"name":"Medical Oncology; Chris O'Brien Lifehouse; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Nagrial","sequence":"additional","affiliation":[{"name":"The Crown Princess Mary Cancer Centre; Westmead Australia"},{"name":"Medical School; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine A","family":"Chantrill","sequence":"additional","affiliation":[{"name":"Medical Oncology; Illawarra Shoalhaven Local Health District; Wollongong Australia"},{"name":"University of Wollongong; Wollongong Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wen","family":"Sim","sequence":"additional","affiliation":[{"name":"Medical Oncology; The Kinghorn Cancer Care Centre, St Vincent's Hospital; Sydney Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine and Health; University of New South Wales; Sydney Australia"},{"name":"NHMRC Clinical Trials Centre; University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Yip","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; The Canberra Hospital; Garran Australia"},{"name":"ANU Medical School; Australian National University; Acton Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa","family":"Chin","sequence":"additional","affiliation":[{"name":"Medical Oncology; The Kinghorn Cancer Care Centre, St Vincent's Hospital; Sydney Australia"},{"name":"School of Clinical Medicine, Faculty of Medicine and Health; University of New South Wales; Sydney Australia"},{"name":"Medical Oncology; Garvan Institute of Medical Research; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"issue":"27","key":"10.1002\/14651858.CD011044.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2006.07.0201","article-title":"Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1684\/bdc.2009.0871","article-title":"First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study","volume":"96","author":"Afchain","year":"2009","journal-title":"Bulletin du Cancer"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/00365528309181646","article-title":"Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU","volume":"18","author":"Andren-Sandberg","year":"1983","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(17)30046-8","article-title":"Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial","volume":"2","author":"Bachet","year":"2017","journal-title":"Lancet Gastroenterology Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0005|cit5","article-title":"Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: a GERCOR randomized phase II study (AFUGEM)","volume":"35","author":"Dubreuil","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD011044.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/annonc\/mdm467","article-title":"Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer","volume":"19","author":"Boeck","year":"2008","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011044.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/1097-0142(19831101)52:9<1577::AID-CNCR2820520906>3.0.CO;2-8","article-title":"Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study","volume":"52","author":"Bukowski","year":"1983","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Moore","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD011044.pub3-BIB0010|cit10","article-title":"Sequential nab-paclitaxel\/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: the SEQUENCE trial","volume":"40","author":"Carrato","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/jco.2004.22.90140.4005","article-title":"Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC)","volume":"22","author":"Cheverton","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/COC.0000000000000260","article-title":"A phase 2 randomized, double-blind, multicenter trial of imexon plus gemcitabine versus gemcitabine plus placebo in patients with metastatic chemotherapy-naive pancreatic adenocarcinoma","volume":"41","author":"Cohen","year":"2018","journal-title":"American Journal of Clinical Oncology: Cancer Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.10323","article-title":"Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and\/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale","volume":"94","author":"Colucci","year":"2002","journal-title":"Cancer"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study","volume":"28","author":"Colucci","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD011044.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2017.35.15_suppl.4100","article-title":"A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC)","volume":"35","author":"Corrie","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD011044.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41416-020-0846-2","article-title":"Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma","volume":"122","author":"Corrie","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"14","key":"10.1002\/14651858.CD011044.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.1985.03350380077025","article-title":"A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin","volume":"253","author":"Cullinan","year":"1985","journal-title":"Journal of the American Medical Association"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y","article-title":"A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin","volume":"65","author":"Cullinan","year":"1990","journal-title":"Cancer"},{"issue":"33","key":"10.1002\/14651858.CD011044.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0021|cit21","article-title":"FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX)","volume":"36","author":"Dahan","year":"2018","journal-title":"Journal of Clinical Oncology: American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"JCO2003329","DOI":"10.1200\/JCO.20.03329","article-title":"Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial","volume":"39","author":"Dahan","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bjc.6602640","article-title":"Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)","volume":"93","author":"Di Costanzo","year":"2005","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdh098","article-title":"Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients","volume":"15","author":"Ducreux","year":"2004","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/1097-0142(19810101)47:1<27::AID-CNCR2820470106>3.0.CO;2-F","article-title":"Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group","volume":"47","author":"Frey","year":"1981","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00423-001-0267-5","article-title":"NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial","volume":"386","author":"Gansauge","year":"2002","journal-title":"Langenbeck's Archives of Surgery"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/curroncol28030164","article-title":"Activity and safety of NAB-FOLFIRI and NAB-FOLFOX as first-line treatment for metastatic pancreatic cancer (NabucCO study)","volume":"28","author":"Giommoni","year":"2021","journal-title":"Current Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1200\/JCO.2018.36.4_suppl.351","article-title":"Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study)","volume":"36","author":"Giommoni","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Annals of Oncology"},{"issue":"24","key":"10.1002\/14651858.CD011044.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer","volume":"24","author":"Heinemann","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD011044.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2007.15.6240","article-title":"Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial\u2014SAKK 44\/00\u2013CECOG\/PAN.1.3.001","volume":"26","author":"Bernhard","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD011044.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","article-title":"Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group","volume":"25","author":"Herrmann","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10147-011-0237-z","article-title":"A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity","volume":"16","author":"Hirao","year":"2011","journal-title":"International Journal of Clinical Oncology"},{"issue":"39","key":"10.1002\/14651858.CD011044.pub3-BIB0034|cit34","first-page":"875","article-title":"Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer","volume":"48","author":"Huguier","year":"2001","journal-title":"Hepato-gastroenterology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011044.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.1016\/j.annonc.2022.04.262","article-title":"P-172 A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC)","volume":"33","author":"Jin","year":"2022","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19910901)68:5<965::AID-CNCR2820680509>3.0.CO;2-2","article-title":"A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma","volume":"68","author":"Kelsen","year":"1991","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/1097-0142(197402)33:2<563::AID-CNCR2820330235>3.0.CO;2-K","article-title":"Proceedings: a controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer","volume":"33","author":"Kovach","year":"1974","journal-title":"Cancer"},{"issue":"33","key":"10.1002\/14651858.CD011044.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2009.22.1309","article-title":"Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904","volume":"27","author":"Kulke","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1097\/MD.0000000000005702","article-title":"A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea","volume":"96","author":"Lee","year":"2017","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/jco.2004.22.90140.4117","article-title":"Chronomodulated (Chrono) vs constant (Cst) rate infusional 5-fluorouracil (FU) with or without cisplatin (CDDP) in patients with advanced or metastatic pancreatic cancer. A multicenter randomized trial of the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer (EORTC 05962)","volume":"22","author":"Levi","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1200\/jco.2004.22.90140.4144","article-title":"A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer","volume":"22","author":"Li","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/annonc\/mdr379","article-title":"Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial","volume":"23","author":"Lohr","year":"2012","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD011044.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"36","key":"10.1002\/14651858.CD011044.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1200\/JCO.2005.02.1980","article-title":"Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group","volume":"23","author":"Lutz","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011044.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"v212","DOI":"10.1093\/annonc\/mdx369.007","article-title":"A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)","volume":"28","author":"Hidalgo","year":"2017","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1200\/JCO.18.00089","article-title":"Phase I\/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2","volume":"37","author":"Macarulla","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD011044.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2002.09.029","article-title":"Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer","volume":"20","author":"Maisey","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0048|cit48","unstructured":"Maisey N There is an error in the published survival curves [personal communication] Email to: V Chin"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2012.283","article-title":"Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas","volume":"107","author":"Meng","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/1097-0142(197708)40:2<605::AID-CNCR2820400202>3.0.CO;2-#","article-title":"Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide","volume":"40","author":"Moertel","year":"1977","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0051|cit51","first-page":"509","article-title":"Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and \"lactones\"","volume":"85","author":"Moertel","year":"1979","journal-title":"Surgery"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdi309","article-title":"A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer","volume":"16","author":"Oettle","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0053|cit53","unstructured":"Ohkawa S Confirmed unpublished HR for OS (personal communication) Email to: V Chin"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1200\/jco.2004.22.90140.4131","article-title":"Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer","volume":"22","author":"Ohkawa","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00280-012-1822-1","article-title":"Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)","volume":"69","author":"Ozaka","year":"2012","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00280-015-2683-1","article-title":"Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study","volume":"75","author":"Petrioli","year":"2015","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0057|cit57","article-title":"Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500)","volume":"40","author":"Philip","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1002\/14651858.CD011044.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","article-title":"Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Poplin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"35","key":"10.1002\/14651858.CD011044.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1200\/JCO.2013.51.0826","article-title":"Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity","volume":"31","author":"Poplin","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1470-2045(05)70175-3","article-title":"Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial","volume":"6","author":"Reni","year":"2005","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-011-1680-2","article-title":"A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)","volume":"69","author":"Reni","year":"2012","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2468-1253(18)30196-1","article-title":"Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterology and Hepatology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD011044.pub3-BIB0063|cit63","article-title":"Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, 6 capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma","volume":"28","author":"Zanon","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0064|cit64","unstructured":"Pelzer U Unpublised OS and PFS data provided (personal communication) Email to: V Chin"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"LBA4009","DOI":"10.1200\/jco.2005.23.16_suppl.lba4009","article-title":"A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer","volume":"23","author":"Riess","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2020.05.018","article-title":"Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: the Federation Francophone de Cancerologie Digestive-PRODIGE37 randomised phase II study (FIRGEMAX)","volume":"136","author":"Rinaldi","year":"2020","journal-title":"European Journal of Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0067|cit67","article-title":"Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5- fluorouracil plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): a randomized phase II study (PRODIGE 37- FIRGEMAX)","volume":"36","author":"Taieb","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD011044.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.2004.12.082","article-title":"Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate","volume":"22","author":"Rocha Lima","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/mdg029","article-title":"Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"iv210","DOI":"10.1093\/annonc\/mdu334.3","article-title":"A phase III trial comparing of FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"25","author":"Singhal","year":"2014","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0959-8049(03)00271-5","article-title":"A phase II\/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer","volume":"39","author":"Smith","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6603301","article-title":"A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer","volume":"95","author":"Stathopoulos","year":"2006","journal-title":"British Journal of Cancer"},{"issue":"24","key":"10.1002\/14651858.CD011044.pub3-BIB0073|cit73","first-page":"2020","article-title":"Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial","volume":"45","author":"Takada","year":"1998","journal-title":"Hepato-gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD011044.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","article-title":"Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma","volume":"21","author":"Tempero","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bjc.1991.265","article-title":"Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas","volume":"64","author":"Topham","year":"1991","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"e000151","DOI":"10.1136\/esmoopen-2016-000151","article-title":"Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study","volume":"2","author":"Hagiwara","year":"2017","journal-title":"European Society of Medical Oncology Open"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00432-017-2349-y","article-title":"Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer","volume":"143","author":"Okusaka","year":"2017","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD011044.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e15109","DOI":"10.1200\/jco.2013.31.15_suppl.e15109","article-title":"Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer","volume":"31","author":"Ueno","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/jco.2004.22.90140.4118","article-title":"Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study","volume":"22","author":"Viret","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MPA.0000000000000742","article-title":"Tumor reduction in primary and metastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: an exploratory analysis from a phase 3 study.","volume":"46","author":"Kunzmann","year":"2017","journal-title":"Pancreas"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/MPA.0000000000001234","article-title":"The benefit-risk balance of nab-paclitaxel in metastatic pancreatic adenocarcinoma","volume":"48","author":"Peron","year":"2019","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/OTT.S124097","article-title":"Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial","volume":"10","author":"Tabernero","year":"2017","journal-title":"OncoTargets and Therapy"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"LBA148","DOI":"10.1200\/jco.2013.31.4_suppl.lba148","article-title":"Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)","volume":"31","author":"Von Hoff","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"LBA661","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA661","article-title":"NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil\/ leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"41","author":"Wainberg","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0086|cit86","first-page":"404","article-title":"Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer","volume":"24","author":"Wang","year":"2002","journal-title":"Chinese Journal of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0087|cit87","first-page":"341","article-title":"Gemcitabine as palliative treatment in patients with unresectable pancreatic cancer previously treated with placement of a covered metal stent. A randomized controlled trial","volume":"13","author":"Xinopoulos","year":"2008","journal-title":"Journal of the Balkan Union of Oncology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0088|cit88","article-title":"Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone: Ax-panc-sy001: a phase II randomized study","volume":"36","author":"Yalcin","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00280-017-3250-8","article-title":"Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer","volume":"79","author":"Yamaue","year":"2017","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08941939.2020.1805057","article-title":"Comparison of image-guided iodine-125 seed interstitial brachytherapy and local chemotherapy perfusion in treatment of advanced pancreatic cancer","volume":"35","author":"Zhou","year":"2020","journal-title":"Journal of Investigative Surgery"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1200\/JCO.2020.38.4_suppl.717","article-title":"Efficacy and safety of nab-paclitaxel plus S-1(nab-P\/S-1) versus nab-paclitaxel plus gemcitabine (nab-P\/Gem) for firstline chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): a randomized study","volume":"38","author":"Zong","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00432-020-03442-0","article-title":"Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study","volume":"147","author":"Zong","year":"2021","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0093|cit93","unstructured":"Abdel-Wahab M El-Shennawy F Agha S Ragab E Fathi O Sultan A Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2) Hepato-gastroenterology 1999 46 Suppl 1 1293 6"},{"issue":"22","key":"10.1002\/14651858.CD011044.pub3-BIB0094|cit94","first-page":"1125","article-title":"Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomized study","volume":"45","author":"Aigner K","year":"1998","journal-title":"Hepato-gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/annonc\/mdi324","article-title":"PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study","volume":"16","author":"Alberts S","year":"2005","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3109\/00365528109181013","article-title":"A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer","volume":"16","author":"Andersen","year":"1981","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1200\/JCO.1988.6.6.1053","article-title":"A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers","volume":"6","author":"Ardalan","year":"1988","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011044.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/COC.0000000000000854","article-title":"Concurrent nab-paclitaxel and radiotherapy: novel radiosensitization for borderline resectable or unresectable pancreatic cancer","volume":"44","author":"Arscott","year":"2021","journal-title":"American Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/COC.0b013e3181d2734a","article-title":"Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma","volume":"34","author":"Astsaturov","year":"2011","journal-title":"American Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0100|cit100","first-page":"733","article-title":"Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer","volume":"60","author":"Baker","year":"1976","journal-title":"Cancer Treatment Reports"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.4122","article-title":"Gemcitabine (G)\/erlotinib (E) versus gemcitabine\/erlotinib\/capecitabine (C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group","volume":"32","author":"Benavides","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Benson A Bendell J Wainberg ZA Acs P Kudrik F A phase 2 randomized, double-blind, placebo controlled study of simtuzumab or placebo in combination with gemcitabine for the first line treatment of pancreatic adenocarcinoma Annals of Oncology 2014 iv210","DOI":"10.1093\/annonc\/mdu334.4"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1634\/theoncologist.2017-0024","article-title":"A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma","volume":"22","author":"Benson","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12032-009-9173-4","article-title":"An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer","volume":"27","author":"Berglund","year":"2010","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0959-8049(17)30330-1","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer","volume":"72 Suppl 1","author":"Boku","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"15","key":"10.1002\/14651858.CD011044.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","article-title":"Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial","volume":"19","author":"Bramhall","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6600446","article-title":"A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer","volume":"87","author":"Bramhall","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD011044.pub3-BIB0108|cit108","article-title":"R0-resection following chemotherapy or chemoradiation improves survival of primary inoperable pancreatic cancer patients. Interim results of the CONKO-007 prospective randomized multicenter trial","volume":"57","author":"Brunner","year":"2019","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00066-020-01680-2","article-title":"R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007+\/- trial","volume":"197","author":"Fietkau","year":"2021","journal-title":"Strahlentherapie und Onkologie"},{"issue":"15S","key":"10.1002\/14651858.CD011044.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/jco.2009.27.15_suppl.4601","article-title":"A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC)","volume":"27","author":"Buanes","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/1097-0142(19930115)71:2<322::AID-CNCR2820710209>3.0.CO;2-G","article-title":"Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study","volume":"71","author":"Bukowski","year":"1993","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/COC.0000000000000068","article-title":"Randomized phase II trial of irinotecan\/docetaxel or irinotecan\/docetaxel plus cetuximab for metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study","volume":"39","author":"Burtness","year":"2016","journal-title":"American Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1179\/joc.2004.16.6.589","article-title":"Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology","volume":"16","author":"Cantore","year":"2004","journal-title":"Journal of Chemotherapy (Florence)"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0114|cit114","article-title":"Second-line (SL) chemotherapy containing oxaliplatin (OXA) in metastatic pancreatic cancer (PC): whom should we trust?","volume":"35","author":"Caparello","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(07)70383-2","article-title":"Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial","volume":"9","author":"Cascinu","year":"2008","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.dld.2013.09.020","article-title":"Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized phase II study","volume":"46","author":"Cascinu","year":"2013","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejca.2021.02.023","article-title":"Nab-paclitaxel\/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial","volume":"148","author":"Cascinu","year":"2021","journal-title":"European Journal of Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/jco.2013.31.15_suppl.4012","article-title":"Final analysis of a phase IB\/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): a University of Chicago phase II consortium study","volume":"31","author":"Catenacci","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1200\/jco.2013.31.15_suppl.3049","article-title":"Phase II study of dendritic cell vaccination combined with recombinant adenovirus-p53 in treatment for patients with advanced pancreatic carcinoma","volume":"31","author":"Chai","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011044.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study","volume":"19","author":"Chauffert","year":"2008","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.canlet.2005.03.027","article-title":"The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression","volume":"233","author":"Chen","year":"2006","journal-title":"Cancer Letters"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"V321","DOI":"10.1093\/annonc\/mdz247.160","article-title":"A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and\/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment","volume":"30 Suppl 5","author":"Chen","year":"2019","journal-title":"Annals of Oncology"},{"issue":"16","key":"10.1002\/14651858.CD011044.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.11569\/wcjd.v25.i16.1511","article-title":"Clinical efficacy of gemcitabine combined with intensity modulated radiotherapy in treatment of pancreatic cancer","volume":"25","author":"Chen","year":"2017","journal-title":"World Chinese Journal of Digestology"},{"issue":"Suppl 8:VIII","key":"10.1002\/14651858.CD011044.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdy282.117","article-title":"Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)15-fluorouracil\/leucovorin (5-FU\/LV): survival analysis from NAPOLI-1","volume":"29","author":"Chen","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2018.09.010","article-title":"Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: expanded analysis of a global phase 3 trial","volume":"105","author":"Chen","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0126|cit126","article-title":"Efficacy and safety of liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU\/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: post-hoc analysis of the NAPOLI-1 trial","volume":"35","author":"Chen","year":"2017","journal-title":"Journal of Clinical Oncology: American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2147\/CMAR.S163475","article-title":"Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer","volume":"10","author":"Chiorean","year":"2018","journal-title":"Cancer Management and Research"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"viii252","DOI":"10.1093\/annonc\/mdy282.123","article-title":"Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC","volume":"29","author":"Chiritescu","year":"2018","journal-title":"Annals of Oncology"},{"issue":"v101","key":"10.1002\/14651858.CD011044.pub3-BIB0129|cit129","article-title":"Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): a quality of life randomized cross-over study (QOLINPAC)","volume":"29","author":"Chiritescu","year":"2018","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ijrobp.2004.05.061","article-title":"A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer","volume":"60","author":"Chung","year":"2004","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1200\/jco.2015.33.15_suppl.4119","article-title":"SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer","volume":"33","author":"Chung","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011044.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.ejca.2008.12.022","article-title":"A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine","volume":"45","author":"Ciuleanu","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0133|cit133","unstructured":"A clinical study to assess the comparative blood concentration of two anti-cancer drugs (test and marketed Irinotecan) when given along with other anti-cancer drugs (fluorouracil and leucovorin) in patients with pancreatic cancer https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/04\/013114"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ijrobp.2004.12.074","article-title":"A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282","volume":"62","author":"Cohen","year":"2005","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/jco.2010.28.15_suppl.4076","article-title":"A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naive pancreatic adenocarcinoma (PC)","volume":"28","author":"Cohen","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1002\/14651858.CD011044.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"18 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0137|cit137","article-title":"Unicancer GI PRODIGE 24\/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas","volume":"36","author":"Conroy","year":"2018","journal-title":"Journal of Clinical Oncology: American Society of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011044.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/gut.2010.216135","article-title":"Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)","volume":"59","author":"Dahan","year":"2010","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/jco.2015.33.15_suppl.3051","article-title":"A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer","volume":"33","author":"Dalgleish","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0140|cit140","first-page":"118","article-title":"First-line liposomal irinotecan + 5-fluorouracil\/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: results from a phase 1\/2 study","volume":"16 Suppl 8","author":"Dean","year":"2020","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/j.annonc.2020.08.2049","article-title":"PRODIGE 65 - UCGI 36 - GEMPAX: a unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma","volume":"31 Suppl 4","author":"De la Fouchardiere","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdv133","article-title":"A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer","volume":"26","author":"Deplanque","year":"2015","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdf197","article-title":"A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma","volume":"13","author":"Ducreux","year":"2002","journal-title":"Annals of Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD011044.pub3-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"viii266","DOI":"10.1093\/annonc\/mdy282.164","article-title":"PRODIGE 29-UCGI 26 (NEOPAN): a randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)","volume":"29","author":"Ducreux","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S1136","DOI":"10.1016\/j.annonc.2022.07.1428","article-title":"1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)","volume":"33","author":"Ducreux","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"viii266","DOI":"10.1093\/annonc\/mdy282.164","article-title":"PRODIGE 29-UCGI 26(NEOPAN): a randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)","volume":"29","author":"Ducreux","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011044.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"TPS499","DOI":"10.1200\/jco.2015.33.3_suppl.tps499","article-title":"A multicenter randomized phase II study of NPC-1C(N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F)","volume":"33","author":"Duffy","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s10637-011-9658-9","article-title":"A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Investigational New Drugs"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"ii105","DOI":"10.1093\/annonc\/mdu193.1","article-title":"Phase 2 Double-blind, placebo-controlled trial of dasatinib added to gemcitabine for subjects with locally-advanced pancreatic cancer (LAPC)","volume":"25","author":"Evans","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0150|cit150","first-page":"285","article-title":"A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer","volume":"6","author":"Friess","year":"2006","journal-title":"BioMed Central Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdv027","article-title":"A phase 3 randomized, double-blind, placebo-controlledtrial of ganitumab or placebo in combination withgemcitabine as first-line therapy for metastaticadenocarcinoma of the pancreas: the GAMMA trial","volume":"26","author":"Fuchs","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/jco.2015.33.15_suppl.4116","article-title":"Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (JCOG 1106)","volume":"33","author":"Fukutomi","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.pan.2017.07.039","article-title":"Clinical trials in progress of chemotherapy for unresectable pancreatic cancer in Japan","volume":"17","author":"Furuse","year":"2017","journal-title":"Pancreatology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0154|cit154","first-page":"SA206","article-title":"HIPEC with gemcitabine as an adjuvant locoregional treatment after radical surgery in pancreatic cancer. Presentation of the clinical trial N-2016-004298-41","volume":"3","author":"Garc\u00eda Santos","year":"2018","journal-title":"Pleura and Peritoneum"},{"issue":"16","key":"10.1002\/14651858.CD011044.pub3-BIB0155|cit155","doi-asserted-by":"publisher","DOI":"10.31487\/j.SCR.2020.07.16","article-title":"Hyperthermic intra-abdominal chemotherapy with gemcitabine as an adjuvant locoregional treatment after radical surgery in pancreatic cancer","volume":"7","author":"Garc\u00eda Santos","year":"2020","journal-title":"Surgical Case Reports"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.4022","article-title":"PANCREOX: A randomized phase 3 study of 5FU\/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT)","volume":"32","author":"Gill","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MPA.0b013e31822ade7e","article-title":"An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer","volume":"41","author":"Gilliam","year":"2012","journal-title":"Pancreas"},{"issue":"11","key":"10.1002\/14651858.CD011044.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1002\/1097-0142(19851201)56:11<2563::AID-CNCR2820561104>3.0.CO;2-0","article-title":"Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma","volume":"56","author":"Gastrointestinal Tumour Study Group","year":"1985","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0159|cit159","first-page":"205","article-title":"A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma","volume":"189","author":"Gastrointestinal Tumor Study Group","year":"1979","journal-title":"Annals of Surgery"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0160|cit160","first-page":"417","article-title":"Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group","volume":"69","author":"Gastrointestinal Trials Study Group","year":"1985","journal-title":"Cancer Treatment Reports"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jnci\/80.10.751","article-title":"Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone","volume":"80","author":"Group Gastrointestinal Tumor Study","year":"1988","journal-title":"Journal of the National Cancer Institute"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1245\/s10434-020-08495-6","article-title":"ASO author reflections: pancreatic cancer patients with germline brca mutations benefit from early introduction of platinum-based chemotherapy","volume":"27","author":"Golan","year":"2020","journal-title":"Annals of Surgical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011044.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/annonc\/mds135","article-title":"BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer","volume":"23","author":"Gon\u00e7alves","year":"2012","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0164|cit164","first-page":"890","article-title":"Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer","volume":"26","author":"Gong","year":"2007","journal-title":"Ai Zheng [Chinese Journal of Cancer]"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"TPS4150","DOI":"10.1200\/jco.2015.33.15_suppl.tps4150","article-title":"ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors-An explorative randomized phase II trial","volume":"33","author":"Haas","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0166|cit166","article-title":"A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type A pancreatic adenocarcinoma","volume":"37","author":"Hall","year":"2019","journal-title":"Journal of Clinical Oncology: American Society of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD011044.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/bjc.2017.128","article-title":"Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data","volume":"116","author":"Hamada","year":"2017","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"LBA4003","DOI":"10.1200\/jco.2013.31.18_suppl.lba4003","article-title":"Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study","volume":"31","author":"Hammel","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0169|cit169","article-title":"A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)","volume":"35","author":"Hammel","year":"2017","journal-title":"Journal of Clinical Oncology: American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2019.10.020","article-title":"Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized phase IIb trial","volume":"124","author":"Hammel","year":"2020","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1443-9573.2006.00243.x","article-title":"Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma","volume":"7","author":"Han","year":"2006","journal-title":"Chinese Journal of Digestive Diseases"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0172|cit172","first-page":"164","article-title":"Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial","volume":"32","author":"Hazel","year":"1981","journal-title":"Journal of the Canadian Association of Radiologists"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/bjc.2013.62","article-title":"Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer","volume":"108","author":"Heinemann","year":"2013","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/gutjnl-2012-302759","article-title":"Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)","volume":"62","author":"Heinemann","year":"2013","journal-title":"Gut"},{"issue":"7","key":"10.1002\/14651858.CD011044.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1200\/JCO.2012.44.7516","article-title":"Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results","volume":"31","author":"Herman","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/jco.2015.33.15_suppl.4006","article-title":"High response rate and PFS with PEGPH20 added to nab-paclitaxel\/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study","volume":"33","author":"Hingorani","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"1-2","key":"10.1002\/14651858.CD011044.pub3-BIB0177|cit177","first-page":"65","article-title":"Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas","volume":"65","author":"Horton","year":"1981","journal-title":"Cancer Treatment Reports"},{"issue":"34","key":"10.1002\/14651858.CD011044.pub3-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578.","article-title":"Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed","volume":"33","author":"Hurwitz","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"TPS4147","DOI":"10.1200\/jco.2015.33.15_suppl.tps4147","article-title":"JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (MPC) after failure or intolerance of first-line chemotherapy","volume":"33","author":"Hurwitz","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0180|cit180","first-page":"S609","article-title":"Comparison of clinical effectiveness of folfirinox versus gemcitabine on quality of life in patients with pancreatic cancer stage IV","volume":"11","author":"Ibraimi","year":"2017","journal-title":"Asian Journal of Pharmaceutics"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/jco.2013.31.4_suppl.291","article-title":"A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"31","author":"Infante","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"e15512","DOI":"10.1200\/jco.2009.27.15_suppl.e15512","article-title":"A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma","volume":"27","author":"Ioka","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/jco.2013.31.4_suppl.287","article-title":"Randomized phase II study of best available fluoropyrimidine compared with continuation of gemcitabine (Gem) monotherapy in patients with Gem-refractory pancreatic cancer","volume":"31","author":"Ioka","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/bjc.2016.436","article-title":"Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer","volume":"116","author":"Ioka","year":"2017","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"IX47","DOI":"10.1093\/annonc\/mdz422.010","article-title":"Liposomal irinotecan (nal-IRI) plus 5-fluorouracil\/levoleucovorin (5 FU\/ LV) vs 5-FU\/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)","volume":"30","author":"Ioka","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.10.004","article-title":"TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)","volume":"106","author":"Ioka","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jjco\/hyaa198","article-title":"Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106","volume":"51","author":"Ioka","year":"2021","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492388","article-title":"Randomized phase II study of consecutive-day versus alternate-day treatment with S-1 as second-line chemotherapy in advanced pancreatic cancer","volume":"96","author":"Ishikawa","year":"2019","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0189|cit189","unstructured":"Full survival data not available Email to V Chin"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1200\/jco.2004.22.90140.4013","article-title":"A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study","volume":"22","author":"Jacobs","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1200\/jco.2011.29.15_suppl.4026","article-title":"Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer","volume":"29","author":"Javle","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.0007-1323.2001.01770.x","article-title":"Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma","volume":"88","author":"Johnson","year":"2001","journal-title":"British Journal of Surgery"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/jhbp.935","article-title":"Neoadjuvant chemotherapy for non-metastatic pancreatic cancer","volume":"28","author":"Jonas","year":"2021","journal-title":"Journal of Hepato-Biliary-Pancreatic Sciences"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3906\/sag-2009-115","article-title":"FOLFIRINOX versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer","volume":"51","author":"Kayahan","year":"2021","journal-title":"Turkish Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/jco.2011.29.4_suppl.238","article-title":"Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma","volume":"29","author":"Kim","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/jco.2008.26.15_suppl.4502","article-title":"Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC)","volume":"26","author":"Kindler","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD011044.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"Kindler","year":"2011","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011044.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1093\/annonc\/mds142","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer","volume":"23","author":"Kindler","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0200|cit200","doi-asserted-by":"crossref","unstructured":"Kindler HL Locker GY Mann H Golan T POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1\/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy Journal of Clinical Oncology 2015","DOI":"10.1200\/jco.2015.33.15_suppl.tps4149"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.1985.3.3.373","article-title":"Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study","volume":"3","author":"Klaassen","year":"1985","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10637-011-9691-8","article-title":"A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma","volume":"30","author":"Ko","year":"2012","journal-title":"Investigational New Drugs"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/jco.2016.34.4_suppl.419","article-title":"RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC)","volume":"34","author":"Ko","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0204|cit204","first-page":"63","article-title":"Induction chemotherapy in locally advanced pancreatic cancer (LAPC)-final results of a multicenter randomized phase 2 AIO trial (NEOLAP)","volume":"43","author":"Hartlapp","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"v253","DOI":"10.1093\/annonc\/mdz247","article-title":"Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel\/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): final results of a multicenter randomised phase II AIO trial","volume":"30","author":"Kunzmann","year":"2019","journal-title":"Annals of Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.2018.36.4_suppl.348","article-title":"Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel\/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP)","volume":"36","author":"Kunzmann","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0207|cit207","first-page":"128","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet: Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0208|cit208","first-page":"A122","article-title":"Multicenter prospective randomized phase II\/III study of neoadjuvant chemoradiation with gemcitabine in patients with borderline resectable pancreatic cancer","volume":"24 Suppl 1","author":"Kwon","year":"2017","journal-title":"Journal of Hepato-Biliary-Pancreatic Sciences"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1007\/s12032-012-0301-1","article-title":"Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies","volume":"29","author":"Lasalvia-Prisco","year":"2012","journal-title":"Medical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD011044.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/jco.2013.31.15_suppl.4040","article-title":"Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer","volume":"31","author":"Le","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011044.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/2051-1426-3-S2-P155","article-title":"Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophophamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinomas (STELLAR)","volume":"3","author":"Le","year":"2015","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0360-3016(03)00435-8","article-title":"Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study","volume":"57","author":"Li","year":"2003","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CAD.0000000000000293","article-title":"Pharmacokinetic study and clinical evaluation of a slow-release 5-fluorouracil implant in pancreatic cancer patients","volume":"27","author":"Li","year":"2016","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1148\/radiology.168.1.3132732","article-title":"Comparison of helium-ion radiation therapy and split-course megavoltage irradiation for unresectable adenocarcinoma of the pancreas. Final report of a Northern California Oncology Group randomized prospective clinical trial","volume":"168","author":"Linstadt","year":"1988","journal-title":"Radiology"},{"issue":"31","key":"10.1002\/14651858.CD011044.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Feng","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011044.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0360-3016(79)90789-2","article-title":"Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Gastrointestinal Tumor Study Group","volume":"5","author":"Lokich","year":"1979","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.2017.35.4_suppl.295","article-title":"Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)","volume":"35","author":"Lowery","year":"2017","journal-title":"Journal of Clinical Oncology: American Society of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0219|cit219","first-page":"1039","article-title":"Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma","volume":"42","author":"Lygidakis","year":"1995","journal-title":"Hepato-gastroenterology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1016\/j.hpb.2019.10.1864","article-title":"Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage ii pancreatic cancer: a prospective, randomized, open-label, single center trial","volume":"21 Suppl 2","author":"Ma","year":"2019","journal-title":"HPB: The Official Journal of the International Hepato Pancreato Biliary Association"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"VIII249","DOI":"10.1093\/annonc\/mdy282.116","article-title":"733P - NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"29 Suppl 8","author":"Macarulla Mercade","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"V101","DOI":"10.1093\/annonc\/mdy149.003","article-title":"Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial","volume":"29 Suppl 5","author":"Macarulla Mercad\u00e9","year":"2018","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MPA.0000000000001455","article-title":"Liposomal Irinotecan + 5-FU\/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial","volume":"49","author":"Macarulla Mercade","year":"2020","journal-title":"Pancreas"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.pan.2017.07.191","article-title":"Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer","volume":"17","author":"Maemura","year":"2017","journal-title":"Pancreatology"},{"issue":"6255","key":"10.1002\/14651858.CD011044.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/bmj.281.6255.1589","article-title":"Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial","volume":"281","author":"Mallinson","year":"1980","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S146039692000117X","article-title":"Concurrent high-dose intensity-modulated radiotherapy and chemotherapy for unresectable locally advanced and metastatic pancreatic cancer: a pilot study","volume":"21","author":"Matsumoto","year":"2022","journal-title":"Journal of Radiotherapy in Practice"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1200\/jco.2008.26.15_suppl.4636","article-title":"A phase IB\/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine","volume":"26","author":"Meyer","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0399-8320(06)73188-8","article-title":"Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial","volume":"30","author":"Mitry","year":"2006","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/jco.2013.31.4_suppl.263","article-title":"Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer","volume":"31","author":"Mizuno","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/jco.2012.30.4_suppl.253","article-title":"Apricot-P: a randomized placebo-controlled phase II study of COX-2 inhibitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarcinoma of the pancreas","volume":"30","author":"Modiano","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","article-title":"Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group","volume":"48","author":"Moertel","year":"1981","journal-title":"Cancer"},{"issue":"17","key":"10.1002\/14651858.CD011044.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1200\/JCO.2003.02.098","article-title":"Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Moore","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD011044.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.21873\/anticanres.14925","article-title":"Efficacy of adjuvant chemotherapy according to the pathological response to neoadjuvant chemotherapy among patients with pancreatic ductal adenocarcinoma","volume":"41","author":"Mori","year":"2021","journal-title":"Anticancer Research"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/bjc.2017.95","article-title":"Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer","volume":"116","author":"Hurt","year":"2017","journal-title":"British Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"VIII243","DOI":"10.1093\/annonc\/mdy282.103","article-title":"SCALOP-2: a multi-centre randomised trial of induction chemotherapy followed by capecitabine 1\/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): results of stage 1 - the non-randomised dose-finding component","volume":"29 Suppl 8","author":"Mukherjee","year":"2018","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD011044.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/bjc.2012.183","article-title":"A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study","volume":"106","author":"Nakai","year":"2012","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0240|cit240","unstructured":"Intrabdominal [sic] hyperthermic chemotherapy and pancreatic cancer https:\/\/clinicaltrials.gov\/study\/NCT03251365?cond=NCT03251365&rank=1"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0241|cit241","unstructured":"A phase II study of gimatecan (ST1481) in locally advanced or metastatic pancreatic cancer https:\/\/clinicaltrials.gov\/study\/NCT04571489?cond=NCT04571489&rank=1"},{"issue":"10073","key":"10.1002\/14651858.CD011044.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0243|cit243","article-title":"ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up","volume":"38","author":"Neoptolemos","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"e14504","DOI":"10.1200\/jco.2010.28.15_suppl.e14504","article-title":"Chemoradiotherapy versus gemcitabine-based chemotherapy in patients with unresectable, locally advanced pancreatic cancer","volume":"28","author":"Nio","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"S1314","DOI":"10.1016\/j.annonc.2020.10.456","article-title":"192P A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: results from the NAPOLEON study","volume":"31 Suppl 6","author":"Nio","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/annonc\/mdv264","article-title":"A phase II\/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer","volume":"26","author":"O'Neil","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"TPS4144","DOI":"10.1200\/jco.2013.31.15_suppl.tps4144","article-title":"Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC)","volume":"31","author":"O'Reilly","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"TPS4146","DOI":"10.1200\/jco.2015.33.15_suppl.tps4146","article-title":"JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy","volume":"33","author":"O'Reilly","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1748-717X-6-124","article-title":"Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD\/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival","volume":"6","author":"Oberic","year":"2011","journal-title":"Radiation Oncology (London)"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0250|cit250","doi-asserted-by":"publisher","first-page":"TPS621","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS621","article-title":"Randomized phase II study of nalicap (nal-IRI\/capecitabine) compared to NAPOLI (nal-IRI\/5-FU\/LV) in gemcitabine-pretreated advanced pancreatic cancer: trial-in-progress","volume":"40","author":"Kim","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/1097-0142(19860101)57:1<29::AID-CNCR2820570108>3.0.CO;2-L","article-title":"Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM)","volume":"57","author":"Oster","year":"1986","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2021.39.15_suppl.4017","article-title":"Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407)","volume":"39","author":"Ozaka","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0254|cit254","unstructured":"Randomized phase II study comparing the standard protocol of gemcitabine with low dose gemcitabine over 6 hours in patients with advanced pancreatic adenocarcinoma https:\/\/pactr.samrc.ac.za\/Search.aspx"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.21037\/jgo-20-238","article-title":"Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41","volume":"12 Suppl 1","author":"Padilla-Valverde","year":"2021","journal-title":"Journal of Gastrointestinal Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bjs.1800810629","article-title":"Chemotherapy prolongs survival in inoperable pancreatic carcinoma","volume":"81","author":"Palmer","year":"1994","journal-title":"British Journal of Surgery"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/jco.2013.31.15_suppl.4054","article-title":"Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma","volume":"31","author":"Pandya","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"S1313","DOI":"10.1016\/j.annonc.2020.10.454","article-title":"Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P\/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)","volume":"31 Suppl 6","author":"Park","year":"2020","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011044.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","article-title":"Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group","volume":"47","author":"Pelzer","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/bjc.2017.67","article-title":"Quality-adjusted survival with combination nal-IRIFU\/LV vs 5-FU\/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis","volume":"116","author":"Pelzer","year":"2017","journal-title":"British Journal of Cancer"},{"issue":"22","key":"10.1002\/14651858.CD011044.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD011044.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.28744","article-title":"Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)","volume":"120","author":"Philip","year":"2014","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"V212","DOI":"10.1093\/annonc\/mdx369.006","article-title":"Nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): interim efficacy and safety results from the phase 2 LAPACT trial","volume":"28 Suppl 5","author":"Philip","year":"2017","journal-title":"Annals of Oncology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0264|cit264","article-title":"Initial gemcitabine\/nab-paclitaxel (GA) followed by sequential (S) mFOLFIRINOX or alternating (A) mFOLFIRI in metastatic pancreatic cancer (mPC): the SEENA-1 study","volume":"35","author":"Picozzi","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0265|cit265","article-title":"A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine refractory metastatic pancreatic cancer patients","volume":"38","author":"Pijnappel","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011044.pub3-BIB0266|cit266","doi-asserted-by":"publisher","first-page":"TPS773","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS773","article-title":"Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC): a randomized phase 3 multicenter study","volume":"41","author":"Pishvaian","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD011044.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/annonc\/mdu176","article-title":"Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma","volume":"25","author":"Propper","year":"2014","journal-title":"Annals of Oncology"},{"issue":"35","key":"10.1002\/14651858.CD011044.pub3-BIB0268|cit268","first-page":"1231","article-title":"A prospective multi-centre study of the response of metastatic gastrointestinal tumours","volume":"104","author":"Queisser","year":"1979","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-010-1343-8","article-title":"A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination","volume":"67","author":"Ramanathan","year":"2011","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00280-009-0995-8","article-title":"Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma","volume":"64","author":"Reni","year":"2009","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"17","key":"10.1002\/14651858.CD011044.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1016\/j.ejca.2013.06.041","article-title":"Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial","volume":"49","author":"Reni","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2018.07.007","article-title":"A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma","volume":"102","author":"Reni","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10637-009-9307-8","article-title":"Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study","volume":"29","author":"Richards","journal-title":"Investigational New Drugs"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/jco.2013.31.15_suppl.4035","article-title":"Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV","volume":"31","author":"Richly","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1200\/jco.2010.28.15_suppl.4033","article-title":"A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial","volume":"28","author":"Riess","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"V260","DOI":"10.1093\/annonc\/mdz247.012","article-title":"Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT)","volume":"30 Suppl 5","author":"Riess","year":"2019","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD011044.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","article-title":"Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer","volume":"49","author":"Rougier","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/jco.2013.31.4_suppl.325","article-title":"TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC)","volume":"31","author":"Ryan","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.pan.2019.05.300","article-title":"Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy after R0 resection for pancreatic ductal adenocarcinoma","volume":"19 Suppl 1","author":"Ryu","year":"2019","journal-title":"Pancreatology"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/PPO.0b013e3181b36264","article-title":"Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas","volume":"15","author":"Saif","year":"2009","journal-title":"Cancer Journal"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0281|cit281","first-page":"195","article-title":"Comparative study of UFT plus mitomycin C and UFT plus doxorubicin in adenocarcinoma. Hirosaki Cooperative Group of Cancer Chemotherapy","volume":"19","author":"Sakata","year":"1992","journal-title":"Gan to Kagaku Ryoho. Cancer & Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","article-title":"Multicenter Phase II study of intravenous and intraperitoneal paclitaxel with s-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis","volume":"265","author":"Satoi","year":"2017","journal-title":"Annals of Surgery"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00595-016-1358-9","article-title":"Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy versus chemotherapy","volume":"47","author":"Satoi","year":"2017","journal-title":"Surgery Today"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4","article-title":"Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report","volume":"42","author":"Schein","year":"1978","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/jco.2013.31.15_suppl.3090","article-title":"VXM01, an oral T-cell vaccine targeting the tumor vasculature: results from a randomized, controlled, first-in-man study in pancreatic cancer patients","volume":"31","author":"Schmitz-Winnenthal","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/jco.2006.24.18_suppl.4102","article-title":"The PACT trial: Interim results of a randomized trial of TNFerade biologic plus chemoradiation (CRT) compared to CRT alone in locally advanced pancreatic cancer (LAPC)","volume":"24","author":"Senzer","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"LBA4012","DOI":"10.1200\/jco.2005.23.16_suppl.lba4012","article-title":"G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study","volume":"23","author":"Shapiro","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0360-3016(01)02806-1","article-title":"Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer","volume":"53","author":"Shinchi","year":"2002","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0289|cit289","first-page":"1407","article-title":"Oral S-1 with concurrent radiotherapy versus S-1 alone in patients with locally unresectable pancreatic cancer","volume":"43","author":"Shinchi","year":"2014","journal-title":"Pancreas. 45th Meeting of the American Pancreatic Association and Japan Pancreas Society"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0290|cit290","first-page":"837","article-title":"The efficacy of preoperative adjuvant treatment for pancreatic ductal adenocarcinoma based on the resectability criteria according to JPS 7th","volume":"44","author":"Shinkai","year":"2017","journal-title":"Gan to Kagaku Ryoho (Cancer & Chemotherapy)"},{"issue":"9630","key":"10.1002\/14651858.CD011044.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0140-6736(08)60661-3","article-title":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study","volume":"371","author":"Spano","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00104-019-0842-3","article-title":"Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer","volume":"90 Supplt 2","author":"Strobel","year":"2019","journal-title":"Der Chirurg (The Surgeon)"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/jco.2013.31.15_suppl.4009","article-title":"Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)","volume":"31","author":"Strumberg","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/s41416-021-01649-7","article-title":"A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study","volume":"126","author":"Su","year":"2021","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00280-013-2368-6","article-title":"Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer","volume":"73","author":"Sudo","year":"2013","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0296|cit296","first-page":"66","article-title":"Randomised Phase I\/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma","volume":"9","author":"Sultana","year":"2009","journal-title":"BioMed Central Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"e14510","DOI":"10.1200\/jco.2011.29.15_suppl.e14510","article-title":"A multicenter randomized phase II trial on Kanglaite Injection (KLT) plus gemcitabine hydrochloride (GEM) versus GEM in patients with local advanced and metastatic pancreatic cancer","volume":"29","author":"Sun","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0298|cit298","first-page":"258","article-title":"Clinical study of S-1 chemotherapy plus high-low oxygen radiotherapy synchronously in treatment of locally advanced pancreatic cancer","volume":"30","author":"Sun","year":"2018","journal-title":"Cancer research and clinic"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00006676-200404000-00023","article-title":"Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer","volume":"28","author":"Sunamura","year":"2004","journal-title":"Pancreas"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"e15023","DOI":"10.1200\/jco.2013.31.15_suppl.e15023","article-title":"A phase IIb trial of coix seed injection for advanced pancreatic cancer","volume":"31","author":"Tagliaferri","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0301|cit301","first-page":"viii244","article-title":"Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer","volume":"29","author":"Taieb","year":"2018","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000227373","article-title":"Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas","volume":"51","author":"Takada","year":"1994","journal-title":"Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MPA.0000000000001227","article-title":"Comparative study between gemcitabine-based and gemcitabine plus S1-based preoperative chemoradiotherapy for localized pancreatic ductal adenocarcinoma, with special attention to initially locally advanced unresectable tumor","volume":"48","author":"Takeuchi","year":"2019","journal-title":"Pancreas"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.pan.2017.05.286","article-title":"A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, +\/- capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back","volume":"17","author":"Tamburrino","year":"2017","journal-title":"Pancreatology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0305|cit305","article-title":"APACT: phase III, multicenter, international, openlabel, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P\/ G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma","volume":"37","author":"Tempero","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/j.annonc.2021.06.009","article-title":"Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): updated 5-year overall survival","volume":"32 Suppl 3","author":"Tempero","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiotherapy Oncology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0308|cit308","first-page":"A657","article-title":"Evaluation of long term survival of chemoradiotherapy with gemcitabine and S-1 compared with chemotherapy alone in the cases with locally advanced pancreatic cancer","volume":"5","author":"Tomishima","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000227250","article-title":"Comparison of single-agent epirubicin and 5-fluorouracil\/epirubicin\/mitomycin in patients with advanced adenocarcinoma of the pancreas","volume":"50","author":"Topham","year":"1993","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/jco.2012.30.15_suppl.4018","article-title":"FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): results of the randomized multicenter AGEO phase II trial FIRGEM","volume":"30","author":"Trouilloud","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"15658","DOI":"10.1200\/jco.2008.26.15_suppl.15658","article-title":"A randomised phase II study of gemcitabine versus mitomycin C versus gemcitabine\/mitomycin C in patients with advanced pancreatic cancer","volume":"26","author":"Tuinmann","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011044.pub3-BIB0312|cit312","article-title":"Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer","volume":"35","author":"Ueno","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD011044.pub3-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"9396","DOI":"10.1002\/cam4.3558","article-title":"Nal-IRI+5-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients","volume":"9","author":"Ueno","year":"2020","journal-title":"Cancer Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"E0169736","DOI":"10.1371\/journal.pone.0169736","article-title":"Clinical and immune effects of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer","volume":"12","author":"Ullenhag","year":"2017","journal-title":"PLOS One"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/sj.bjc.6600883","article-title":"Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma","volume":"88","author":"Ulrich-Pur","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0316|cit316","unstructured":"A prospective, multi-center randomized phase 3 trial of carbon ion versus conventional photon radiation therapy for locally advanced, unresectable pancreatic cancer https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_his_list.cgi?recptno=R000032763"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD011044.pub3-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"TPS4148","DOI":"10.1200\/jco.2013.31.15_suppl.tps4148","article-title":"Efficacy and safety of gemcitabine in combination with TH-302 compared with gemcitabine in combination with placebo in previously untreated patients with metastatic or locally advanced unresectable pancreatic adenocarcinoma: the MAESTRO trial","volume":"31","author":"Van Cutsem","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011044.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/bjc.2014.494","article-title":"Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study","volume":"111","author":"Van Cutsem","year":"2014","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/jco.2015.33.3_suppl.344","article-title":"Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0322|cit322","first-page":"584","article-title":"Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study","volume":"9","author":"Von Hoff","year":"1990","journal-title":"Journal of Biological Response Modifiers"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/annonc\/mdu193.3","article-title":"Napoli-1: Randomized phase 3 study of MM-398 (Nal-Iri), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy","volume":"25","author":"Von Hoff","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/jco.2006.24.18_suppl.4112","article-title":"A randomized phase II study comparing gemcitabine plus nadroparine versus gemcitabine in patients with locally advanced or metastatic pancreatic carcinoma: the GEMFRAX trial","volume":"24","author":"Voorthuizen","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0959-8049(01)00319-7","article-title":"Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial","volume":"38","author":"Wagener","year":"2002","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2021.03.028","article-title":"First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I\/II study","volume":"151","author":"Wainberg","year":"2021","journal-title":"European Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0327|cit327","first-page":"736","article-title":"Effect of qi replenishing and blood circulation activating drugs in treatment of middle-advanced pancreatic cancer with radio- and chemotherapy","volume":"20","author":"Wang","year":"2000","journal-title":"Zhongguo Zhong Xi Yi Jie He za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"issue":"7","key":"10.1002\/14651858.CD011044.pub3-BIB0328|cit328","first-page":"433","article-title":"Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer","volume":"26","author":"Wang","year":"2004","journal-title":"Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]"},{"issue":"20","key":"10.1002\/14651858.CD011044.pub3-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"18162","DOI":"10.18632\/oncotarget.4216","article-title":"Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0331|cit331","first-page":"18","article-title":"A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia","volume":"6","author":"Wiedenmann","year":"2008","journal-title":"Journal of Supportive Oncology"},{"issue":"11","key":"10.1002\/14651858.CD011044.pub3-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/sj.bjc.6605420","article-title":"Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine\/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study","volume":"101","author":"Wilkowski","year":"2009","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD011044.pub3-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdt066","article-title":"Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer","volume":"24","author":"Wolpin","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/jco.2006.24.18_suppl.4116","article-title":"A phase III trial of virulizin plus gemcitabine vs. gemcitabine alone in advanced pancreatic cancer: results of subgroup analysis","volume":"24","author":"Wright","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/cas.12674","article-title":"Randomized phase II\/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study","volume":"106","author":"Yamaue","year":"2015","journal-title":"Cancer Science"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0336|cit336","first-page":"94","article-title":"Peripancreatic arterial ligation combined with arterial infusion regional chemotherapy for treating patients with advanced pancreatic carcinoma","volume":"13","author":"Yongxiang","year":"2001","journal-title":"Journal of Xi'an Medical University (English Edition)"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","article-title":"A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer","volume":"101","author":"Yoo","year":"2009","journal-title":"British Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD011044.pub3-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"747","DOI":"10.5306\/wjco.v11.i9.747","article-title":"Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach","volume":"11","author":"You","year":"2020","journal-title":"World Journal of Clinical Oncology"},{"issue":"5-6","key":"10.1002\/14651858.CD011044.pub3-BIB0339|cit339","first-page":"179","article-title":"Ukrain (NSC-631570) in the treatment of pancreas cancer","volume":"26","author":"Zemskov","year":"2000","journal-title":"Drugs under Experimental and Clinical Research"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0340|cit340","first-page":"400","article-title":"Effects of Guben Yiliu II combined with arterial perfusion with chemotherapeutic agent in treating advanced pancreatic cancer","volume":"27","author":"Zhang","year":"2007","journal-title":"Zhongguo Zhong Xi Yi Jie He za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0341|cit341","first-page":"109","article-title":"Effect of S-l combined with oxaliplatin in the advanced pancreatic cancer and the level of immunocyte","volume":"31","author":"Zhang","year":"2019","journal-title":"Cancer Research and Clinic"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0342|cit342","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS537","article-title":"ACELARATE: a phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma","volume":"36","author":"Palmer","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD011044.pub3-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"TPS4190","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4190","article-title":"Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial","volume":"40","author":"Portales","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0344|cit344","volume-title":"Cancer Facts & Figures 2022","author":"American Cancer Society","year":"2022"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0345|cit345","volume-title":"Cancer Data in Australia","author":"Australian Institute of Health and Welfare (AIHW)","year":"2022"},{"issue":"7592","key":"10.1002\/14651858.CD011044.pub3-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement","volume":"16","author":"Callery","year":"2009","journal-title":"Annals of Surgical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD011044.pub3-BIB0348|cit348","doi-asserted-by":"publisher","first-page":"e108749","DOI":"10.1371\/journal.pone.0108749","article-title":"A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer","volume":"9","author":"Chan","year":"2014","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0349|cit349","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0350|cit350","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0351|cit351","first-page":"471","article-title":"Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis","volume":"14","author":"Gresham","year":"2014","journal-title":"BioMed Central Cancer"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0352|cit352","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/zh-hans\/handbook\/archive\/v5.1\/"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0147-0272(77)80001-9","article-title":"Cancer of the pancreas","volume":"2","author":"Howard","year":"1977","journal-title":"Current Problems in Cancer"},{"issue":"27","key":"10.1002\/14651858.CD011044.pub3-BIB0354|cit354","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","article-title":"Pancreatic cancer: a review of epidemiology, trend, and risk factors","volume":"27","author":"Hu","year":"2021","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0355|cit355","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies [last updated September 2024]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD011044.pub3-BIB0356|cit356","doi-asserted-by":"publisher","first-page":"e104346","DOI":"10.1371\/journal.pone.0104346","article-title":"Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2014","journal-title":"PLOS One"},{"issue":"10242","key":"10.1002\/14651858.CD011044.pub3-BIB0357|cit357","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic Cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0358|cit358","doi-asserted-by":"publisher","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2214\/AJR.09.4110","article-title":"Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know","volume":"195","author":"Nishino","year":"2010","journal-title":"American Journal of Roentgenology"},{"issue":"9","key":"10.1002\/14651858.CD011044.pub3-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"Journal of the American Medical Association"},{"issue":"5","key":"10.1002\/14651858.CD011044.pub3-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2014.01.001","article-title":"Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis","volume":"46","author":"Petrelli","year":"2014","journal-title":"Digestive and Liver Diseases"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0362|cit362","volume-title":"Understanding Radiotherapy. A Guide for People with Cancer, their Families and Friends","author":"Queensland Cancer Fund","year":"2012"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0363|cit363","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"6","key":"10.1002\/14651858.CD011044.pub3-BIB0364|cit364","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.3390\/curroncol30060404.","article-title":"Review of current systemic therapy and novel systemic therapy for pancreatic ductal adenocarcinoma","volume":"30","author":"Sarfraz","year":"2023","journal-title":"Current Oncology"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0365|cit365","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0366|cit366","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program (SEER) Cancer Stat Facts: Pancreatic Cancer [Webpage] https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0367|cit367","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD011044.pub3-BIB0368|cit368","doi-asserted-by":"publisher","first-page":"e2145515","DOI":"10.1001\/jamanetworkopen.2021.45515","article-title":"Comparative outcomes of first-line chemotherapy for metastatic pancreatic cancer among the regimens used in Japan: a systematic review and network meta-analysis","volume":"5","author":"Takumoto","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0369|cit369","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0370|cit370","volume-title":"Pancreatic Cancer","author":"Von Hoff","year":"2005"},{"key":"10.1002\/14651858.CD011044.pub3-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJM199202133260706","article-title":"Pancreatic carcinoma","volume":"326","author":"Warshaw","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"3352\u201374","DOI":"10.1002\/jcp.26183","article-title":"Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: a network meta-analysis","volume":"233","author":"Zhang","year":"2018","journal-title":"Journal of Cellular Physiology"},{"issue":"3","key":"10.1002\/14651858.CD011044.pub3-BIB0373|cit373","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011044.pub2","article-title":"Chemotherapy and radiotherapy for advanced pancreatic cancer.","author":"Chin","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011044.pub3-BIB0374|cit374","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002093","article-title":"Chemotherapy and radiotherapy for pancreatic cancer","author":"Yip","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011044.pub3-BIB0375|cit375","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002093.pub3","article-title":"Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer","author":"Yip","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T17:08:02Z","timestamp":1748452082000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011044.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":375,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011044.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}